Paclitaxel by 96-hour continuous infusion in combination with cisplatin: A phase I trial in patients with advanced lung cancer

Journal of Clinical Oncology

Volumn 15, Issue 2, 1997, Pages 735-743

  Georgiadis, M S ^a   Schuler, B S ^a   Brown, J E ^a   Kieffer, L V ^a   Steinberg, S M ^a   Wilson, W H ^a   Takimoto, C H ^a   Kelley, M J ^a   Johnson, B E ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALE; MAXIMUM PERMISSIBLE DOSE; MUCOSA INFLAMMATION; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

EID: 0031029848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.2.735     Document Type: Article

References (32)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311:899-909, 1995
2. Ihde DC: Drug therapy: Chemotherapy of lung cancer. N Engl J Med 327:1434-1441, 1992
3. Rowinsky EK, Donehower RC: Drug therapy: Paclitaxel (Taxol). N Engl J Med 332:1004-1014, 1995
4. Murphy WK, Fossella FV, Winn RJ, et al.: Phase II study of Taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst 85:384-388, 1993
5. Chang AY, Kim K, Glick J, et al.: Phase II study of Taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85:388-394, 1993
6. Hainsworth JD, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609-1614, 1995
7. Millward MJ, Bishop JF, Friedlander M, et al.: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 14:142-148, 1996
8. Ettinger DS, Finkelstein DM, Sarma RP, et al.: Phase II study of paclitaxel in patients with extensive-stage small cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol 13:1430-1435, 1995
9. Liebmann J, Cook JA, Lipschultz C, et al.: The influence of Cremophor EL on the cell cycle effects of paclitaxel (Taxol) in human tumor cell lines. Cancer Chemother Pharmacol 33:331-339, 1994
10. Georgiadis MS, Schuler B, Johnson BE: Four-day paclitaxel infusion with cisplatin for patients with lung cancer. Semin Oncol 22:67-69, 1995
11. Wilson WH, Berg SL, Bryant G, et al.: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/ II trial of 96-hour infusion. J Clin Oncol 12:1621-1629, 1994
12. Wilson WH, Chabner BA, Bryant G, et al.: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphoma. J Clin Oncol 13:381-386, 1995
13. Rowinsky EK, Gilbert MR, McGuire WP, et al.: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
14. Wittes RE: Appendix A: Grading of Toxicity, in Manual of Oncologic Therapeutics 1989/1990. Philadelphia, PA, Lippincott, 1989, pp 445-448
15. Shaw GL, Gazdar AF, Phelps R, et al.: Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing. Cancer Res 53:5181-5187, 1993
16. Ihde DC, Mulshine JL, Kramer BS, et al.: Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol 12:2022-2034, 1994
17. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33:48-52, 1993
19. Le Chevalier T, Brisgand D, Douillard JY, et al.: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 12:360-367, 1994
20. Langer CJ, Leighton JC, Comis RL, et al.: Paclitaxel and carboplatin in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
21. Bonomi P, Kim K, Chang A, et al.: Phase III trial comparing etoposide-cisplatin versus Taxol with cisplatin-G-CSF versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group trial. Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1145)
22. Seidman AD, Tiersten A, Hudis C, et al.: Phase II trial of paclitaxel by 3-hour infusion as initial and salvage therapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995
23. Seidman AD, Hochhauser D, Gollub M, et al.: Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996
24. Wolff SN, Grosh WW, Prater K, et al.: In vitro pharmacodynamic evaluation of VP-16-213 and implications for chemotherapy. Cancer Chemother Pharmacol 19:246-249, 1987
25. Slevin ML, Clark PI, Joel SP, et al.: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 7:1333-1340, 1989
26. Rowinsky EK, Chaudhry V, Forastiere AA, et al.: Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: Neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010-2020, 1993
27. Eisenhauer EA, Huinink WW, Swenerton KD, et al.: European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: High-dose versus low-dose and long versus short infusion. J Clin Oncol 12:2654-2666, 1994
28. Spriggs DR, Tondini C: Taxol administered as a 120 hour infusion. Invest New Drugs 10:275-278, 1992
29. Von Hoff DD, Schilsky R, Reichert CM, et al.: Toxic effects of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63:1527-1531, 1979
30. Kris MG, Gralla RJ, Wertheim MS, et al.: Trial of the combination of mitomycin, vindesine, and cisplatin in patients with advanced non-small cell lung cancer. Cancer Treat Rep 70:1091-1096, 1986
31. Scagliotti GV, Lodico D, Gozzelino F, et al.: Unresectable non-small cell lung cancer chemotherapy with high-dose cisplatin and etoposide. Oncology 42:224-228, 1985
32. Gralla RJ, Casper ES, Kelson DP, et al.: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 95:414-420, 1981